LEADING EDGE MATERIALS ANNOUNCES CHANGE OF SWEDISH CERTIFIED ADVISER TO SVENSK KAPITALMARKADSGRANSKNING (“SKMG”)
Vancouver, June 9, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces signing of an agreement with Svensk Kapitalmarkadsgranskning (“SKMG”) for an assignment as Certified Adviser for the Nasdaq First North Growth Market (Stockholm).
SKMG will commence as Certified Adviser starting June 16, 2025. Prior to that date, Mangold Fondkommission AB (“Mangold”) will fulfill duties as the Company’s Certified Adviser. The Company would like to thank Mangold for its support since June 2018.
On behalf of the Board of Directors,
Leading Edge Materials Corp.
Kurt Budge, CEO
For further information, please contact the Company at:
info@leadingedgematerials.com
www.leadingedgematerials.com
About Leading Edge Materials
Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden), and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania).
Additional Information
The information was submitted for publication through the agency of the contact person set out above, on June 9, 2025, at 14:30 AM Vancouver time.
Leading Edge Materials is listed on the TSXV under the symbol “LEM”, OTCQB under the symbol “LEMIF” and Nasdaq First North Stockholm under the symbol “LEMSE”. Mangold Fondkommission AB is the Company’s Certified Adviser on Nasdaq First North Growth Market and may be contacted via email CA@mangold.se or by phone +46 (0) 8 5030 1550.
Reader Advisory
This news release may contain statements which constitute “forward-looking information”, including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, changes in the Company’s intended use of proceeds from the Private Placement, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.
Attachment
- 20250609 LEM – Press Release – Change of Certified Adviser FINAL
- Discover Key Insights in Las Vegas Real Estate Market Report for Spring 2025 - June 9, 2025
- MediPharm Labs’ Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident - June 9, 2025
- AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer’s Disease - June 9, 2025
